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Abstract: Antibodies have found applications in several fields,
including, medicine, diagnostics, and nanotechnology, yet
methods to modulate antibody–antigen binding using an
external agent remain limited. Here, we have developed
photoactive antibody fragments by genetic site-specific replace-
ment of single tyrosine residues with photocaged tyrosine, in an
antibody fragment, 7D12. A simple and robust assay is adopted
to evaluate the light-mediated binding of 7D12 mutants to its
target, epidermal growth factor receptor (EGFR), on the
surface of cancer cells. Presence of photocaged tyrosine
reduces 7D12-EGFR binding affinity by over 20-fold in two
out of three 7D12 mutants studied, and binding is restored
upon exposure to 365 nm light. Molecular dynamics simula-
tions explain the difference in effect of photocaging on 7D12-
EGFR interaction among the mutants. Finally, we demonstrate
the application of photoactive antibodies in delivering fluo-
rophores to EGFR-positive live cancer cells in a light-depen-
dent manner.
Introduction
Chemists and biochemists have successfully designed
molecular systems that can be controlled in a defined manner
in response to external agents, such as pH, light, and small
molecules.[1] Controlling the activity of small molecules and
biomolecules has allowed development of molecular ma-
chines, novel drugs, and nano-delivery systems, that have
found widespread applications.[2] Monoclonal antibodies are
arguably one of the most versatile biomolecules that can be
adapted to bind to different substrates with high selectively
and specificity. Due to these properties, antibodies have found
applications as building blocks in molecular electronics, as
agents for detection of substrates in medical diagnosis and
biotechnology, and as inhibitors of biological processes in
biotherapeutics.[3]
Modulating antibody–antigen binding presents an oppor-
tunity to gain user-defined control over antibody-mediated
processes. Despite immense potential, there are only a few
reports on controlling the binding of antibodies to their
target. Notable examples are, antibodies activated by tumor-
specific proteases, and those activated by phosphatases. The
former are currently under investigation for cancer therapy,
and are generated by extending the N-terminal domain of the
antibody.[4] The latter have been generated by chemically
attaching phosphate to cysteine in an antibody fragment.[5]
These approaches are restricted by the availability of sites for
inhibitory groups, and dependent on addition of the activating
enzyme. A method where a controllable functional group can
be incorporated at any site in an antibody, would allow wide
applicability. In addition, adopting light as an activator, would
present the opportunity to gain spatial and temporal control
over antigen-antibody binding in a facile manner, independ-
ent of other molecules.
Selective therapeutic targeting of cells is a major chal-
lenge in medicine, particularly in cancer therapy. Light-
activated small molecule cytotoxic drugs are currently under
investigation for treatment of cancer, that could target cells in
a localized area.[6]However, after photoactivation these drugs
are often not cell-selective, and could cause side effects. Many
antibodies and antibody–drug conjugates (ADCs) are in use,
or in clinical trials, for treatment of cancer.[7] These antibodies
exert cytotoxicity by binding and blocking the function of
receptors on the surface of cancer cells, and in the case of
ADCs, also delivering cytotoxic drugs to cancer cells. As the
same cell surface receptors are often present on healthy cells,
therapeutic antibodies can have severe side effects.[8] To
partly address this challenge, antibodies linked to light-
activated small molecule drugs have also been developed.[9]
However, the antibody would still be able to bind to healthy
cells independent of light. Light-activatable antibodies have
also been generated by non-specific coating of antibodies with
1-(2-nitrophenyl)ethanol using a chemical method.[10] How-
ever, this method generates non-homogeneously labelled
antibody samples, limiting future therapeutic applications.
Site-specific modification of antibodies would allow develop-
ment of homogeneous therapeutic antibodies. Developing
such homogenously modified antibodies, where antigen bind-
ing could be directly controlled using light, at the site of
cancer, would be useful to minimize the side effects of
antibody-based therapeutics.
[*] T. Bridge, Dr. S. A. Shaikh, Dr. A. Sachdeva
School of Chemistry, University of East Anglia
Norwich NR4 7TJ (UK)
E-mail: a.sachdeva@uea.ac.uk
Dr. P. Thomas
The Henry Wellcome Laboratory of Cell Imaging, University of East
Anglia, Norwich NR4 7TJ (UK)
Dr. J. Botta, Dr. P. J. McCormick
Centre of Endocrinology, William Harvey Research Institute
Queen Mary University London
Charterhouse Square, London EC1M 6BQ (UK)
Supporting information and the ORCID identification number(s) for
the author(s) of this article can be found under https://doi.org/10.
1002/anie.201908655.
Angewandte
ChemieResearch Articles
17986 T 2019 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2019, 58, 17986 – 17993
Over the last two decades, genetic code expansion has
enabled site-specific incorporation of unnatural amino acids,
including amino acids containing bioorthogonal functional
groups, photoreactive amino acids and photocaged amino
acids, into proteins.[11] Photocaged amino acids, in particular,
have been employed to control the activity of several
biomolecules including DNA polymerase,[1d] RNA poly-
merase,[12] kinases,[13] proteases[14] and inteins,[15] which have
undoubtedly advanced our understanding of key biological
processes. To the best of our knowledge, site-specifically
incorporated photocaged amino acids have not been used to
control the activity of therapeutically significant antibodies.
In the present study, we show that modifying a single amino
acid to its photocaged counterpart in the antigen binding
region of an antibody fragment, 7D12, inhibits its binding to
its target, epidermal growth factor receptor (EGFR). EGFR
is overexpressed in several cancers, including colorectal
cancer, lung cancer, and head and neck cancer. Therapeutic
antibodies that bind to the extracellular domain of EGFR,
block its downstream signaling and inhibit cell growth;[16]
however, these can cause severe side effects.[17] 7D12 belongs
to a class of single domain antibody fragments isolated from
camelids that have gained importance due to their small size
and deep tissue penetration,[18] and has shown promise in
treatment of cancers in mice model.[19]
Here, we demonstrate efficient genetic site-specific in-
corporation of photocaged tyrosine (pcY) into 7D12, gen-
erating photoactive antibodies. Using an on-cell assay, we
show that the presence of a photocaging group at specific
tyrosine residues in the antigen binding region of 7D12
inhibits its binding to EGFR on the surface of cancer cells and
the binding is restored upon irradiation with 365 nm light. In
order to explain why the binding of 7D12 to EGFR is affected
by pcY at only certain positions at the binding interface, we
investigated the 7D12-EGFR interaction using molecular
dynamics simulations. Finally, we show that these photoactive
antibodies mediate light-dependent delivery of small mole-
cule fluorophores to the surface of EGFR-positive live cancer
cells.
Results and Discussion
Efficient genetic site-specific incorporation of photocaged
tyrosine into antibody fragments. Wild-type 7D12 (wt7D12)
was cloned into pSANG10 plasmid,[20] (Page S3 and Fig-
ure S1) and expressed in E. Coli, resulting in a high yield
(10.1 mg of wt7D12 per litre of culture, Figure S2); pSANG10
has earlier been employed for efficient expression of single
chain antibody fragments in the periplasm of E. coli.[20]
To design photoactive mutants of 7D12, we aimed to
replace tyrosine residues with pcY in the antigen binding site
of 7D12. Mutants of M. jannaschii Tyrosyl-tRNA synthetase
(MjRS)/MjtRNA pair and Methanosarcina Pyrrolysyl-tRNA
synthetase (PylRS)/tRNA pair have been employed earlier to
genetically encode pcY.[21] Several suppressor plasmids are
known, that contain orthogonal aminoacyl-tRNA synthetase
(aaRS)/tRNA pairs for incorporation of unnatural amino
acids in response to an amber (TAG) stop codon, in E. coli.[22]
These plasmids vary in their origin of replication, promotors
that drive the expression of aaRS and tRNA, and the copy
number of aaRS and tRNA genes. To find an optimal plasmid
system and aaRS/tRNA pair for incorporation of pcY in
7D12, we screened five suppressor plasmids containing either
MjCNFRS/MjtRNACUA pair (MjCNFRS is an MjRS evolved
for incorporation of 4-cyano-l-phenylalanine) or the PylRS/
tRNACUA pair (Page S3 and S4, and Figure S3 and S4).
pULTRA plasmid with MjCNFRS/MjtRNACUA pair, and
pCDF plasmid with PylRS/tRNACUA pair show most efficient
genetic incorporation of unnatural amino acids. Due to the
ease of cloning, we selected pULTRA and the MjCNFRS/
MjtRNACUA pair, replacing the MjCNFRS with MjpcYRS
(aaRS evolved for pcY) (Page S3).
Examining the crystal structure of 7D12 bound to domain
III of EGFR (PDB ID: 4KRL),[23]we identified three tyrosine
residues in the antigen binding site of 7D12, viz. Y32, Y109
and Y113, as candidates for developing photocaged mutants
(Figure 1A). These were replaced with pcY by assigning
amber stop codon, TAG, to these positions, forming the
mutants, 7D12pcY32, 7D12pcY109, and 7D12pcY113, re-
spectively. Protein expression was performed both, in the
presence, and absence, of pcY. For the amber mutants,
expression of full-length protein was observed only on
addition of pcY (Figure 1B). High yields of amber mutants
with pcY were obtained after purification: 5.3 mg of
7D12pcY32, 3.2 mg of 7D12pcY109, and 1.7 mg of
7D12pcY113, per litre of culture. Electrospray ionization
mass spectrometry (ESI-MS) analysis of full-length 7D12 and
the mutants was consistent with incorporation of pcY (Fig-
ure S5).
Figure 1. Genetic site-specific incorporation of pcY in 7D12. A) Crystal
structure of 7D12 (grey)–EGFR domain III (yellow) complex (PDB ID:
4KRL)[23] showing Y32, Y109, and Y113 (pink) in the antigen binding
pocket of 7D12, that were replaced with pcY. B) The expression of
three amber mutants of 7D12, viz. 32TAG, 109TAG and 113TAG only
occurs in the presence of pcY. Comparison of band intensities for
amber mutants with wt7D12 shows efficient incorporation of pcY.
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Assessing the binding of photoactive antibodies to EGFR
on the surface of cancer cells. To study 7D12-EGFR binding,
we adopted an assay that would report on this interaction in
a cellular environment where other cell surface antigens are
also present. For this purpose, A431 cells were used; these are
human epidermal carcinoma cells with high levels of EGFR
on their cell surface, and have been used previously to study
EGFR targeting anti-cancer drugs.[19b,24] In our on-cell assay
(Figure 2A), 7D12 and its mutants were incubated with live
A431 cells in a 96-well plate, in media containing serum at
37 8C, thus allowing the binding to occur under physiologically
relevant conditions. Following this, unbound 7D12 was
removed, cells were fixed to the surface of the plate, and
the bound 7D12 was assessed via its C-terminus hexa-
Figure 2. Assessing the binding of photocaged mutants of antibody fragment to EGFR on cell surface. A) Schematic representation of procedure
followed for measurement of 7D12–EGFR binding on the surface of A431 cancer cells. 1. 40000 cells were seeded into each well of a 96-well
plate. 2. These cells were incubated with the complete media containing the antibody fragment. 3. The antibody solution was replaced with 3.7%
formaldehyde solution for fixing the cells. 4. Incubation with blocking solution. 5. Incubation with primary antibody specific for hexa-histidine tag.
6. incubation with HRP-linked secondary antibody. 7. The substrate for HRP was added and the cells were imaged for chemiluminescence
(Page S5). B) Comparison of ESI-MS of photocaged mutants of 7D12 before and after irradiation with 365 nm light confirms light-mediated
decaging. See Page S6 for decaging conditions. C) The on-cell binding assay demonstrates that the presence of pcY at positions 32 and 113 in
7D12 inhibits its binding to EGFR. 7D12pcY109 mutant does not show inhibition in binding to EGFR. Binding of 7D12pcY32 and 7D12pcY113 is
restored upon irradiation with 365 nm light. These experiments were performed in triplicate (Figure S8). D) Chemiluminescence intensity was
quantified using a CLARIOstar plate reader and plotted against concentration of 7D12, where X-axis is in log scale; the data was fitted to
a sigmoidal nonlinear curve using GraphPad (Figure S9). Some error bars are too small to be clearly visible.
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histidine (His6) tag (Figure 2A, and Page S5). Unlike several
other techniques used for measuring protein-protein inter-
action, this approach does not require sophisticated instru-
mentation or purified EGFR, and assesses the binding of
antibody to EGFR on a cell surface. The technique is similar
to whole cell enzyme-linked immunosorbent assay (ELISA),
and on-cell western used for quantification of cell surface
antigens.[25] A series of control experiments were performed
to demonstrate the viability of the on-cell assay used in this
study. When 7D12 was incubated with MDA-MB-231, a cell
line with low levels of EGFR, often used as a negative
control,[24] the chemiluminescence signal was significantly
lower compared to the signal for A431 cancer cell line
(Figure S6). This supports our premise that the observed
chemiluminescence is due to specific interaction between
7D12 and EGFR, and not due to non-specific binding of 7D12
to the cell surface. We also measured the binding of an
unrelated His6-tagged antibody fragment, RR6-VHH,[26] to
A431 cells using this assay. Near-background level of chem-
iluminescence was observed with RR6-VHH, demonstrating
that the observed signal is not due to the non-specific
interaction of antibody fragments with A431 cancer cells
(Figure S7). Prior to measuring the binding of photocaged
mutants of 7D12, we used ESI-MS to confirm light-mediated
decaging of 7D12pcY32, 7D12pcY109, and 7D12pcY113. The
molecular weight of all the pcY mutants was reduced to that
of wt7D12 after irradiation with 365 nm light for 4 min,
confirming the loss of o-nitrobenzyl group from tyrosine
residues in the photocaged mutants (Figure 2B).
On performing the on-cell assay, it was observed that for
wt7D12, as the concentration was increased from 0 to 100 nm,
an increase in chemiluminescence occurs, followed by satu-
ration of signal at higher concentration (Figure 2C). For the
7D12pcY32 and 7D12pcY113 mutants, near-background
chemiluminescence signal was observed even up to 500 nm
concentration (Figure 2C and Figure S8), demonstrating that
7D12-EGFR binding is inhibited due to the presence of pcY
at positions 32 and 113 in 7D12. Interestingly, pcY at position
109, despite being at the binding interface, does not inhibit
7D12-EGFR binding. We explain this difference in binding
behaviour of mutants using computational simulations later in
this study. Upon irradiating with 365 nm light (Page S5),
7D12pcY32 and 7D12pcY113 exhibit chemiluminescence
signals similar to wt7D12, consistent with 7D12-EGFR
binding. This experiment demonstrates light-mediated acti-
vation of antibody-antigen binding in 7D12 mutants (Fig-
ure 2C).
We estimated the binding affinity of 7D12 to EGFR on
the surface of A431 cells from the chemiluminescence signal
measured as a function of the concentration of 7D12 (Fig-
ure 2D and Figure S9). The KD for wt7D12 and 7D12pcY109
before irradiation with 365 nm light were estimated to be
23(: 2.6) nm and 31(: 1.5) nm, respectively. The KD for
wt7D12 calculated here is in close agreement with the value
reported in a previous study.[19a] For caged 7D12pcY32 and
7D12pcY113, theKD is expected to be greater than 500 nm, as
near-background chemiluminescence was observed till
500 nm concentration. After irradiation with 365 nm light,
the KD for wt7D12, and decaged 7D12pcY32, 7D12pcY109,
and 7D12pcY113, were estimated to be 20(: 1.8) nm, 37(:
2.6) nm, 27(: 1.6) nm and 38(: 2.6) nm, respectively. For
decaged 7D12pcY32 and 7D12pcY113, the chemilumines-
cence intensity at saturation is 86% and 76%, respectively, of
the intensity for wt7D12; indicating that binding is recovered
up to these levels (Figure S9). Accordingly, the KD for
decaged 7D12pcY32 and 7D12pcY113 are higher than for
wt7D12.
For such photocaged antibodies to be useful in the clinic,
the effect of 365 nm light as a cause for cell toxicity needs to
be examined. Hence, we performed experiments to assess the
viability of A431 cells after irradiation with 365 nm light for
4 min, which were the same conditions as for 7D12 decaging.
The cells were then allowed to proliferate for 48 h, and cell
viability was examined using the resazurin assay (Page S6 and
Figure S10).[27] The number of viable cells reduced by & 12%
upon irradiation, leaving 88% cells viable- demonstrating
that radiation exposure conditions used for decaging 7D12
causes low toxicity in A431 cells.
Molecular dynamics (MD) simulations explain the differ-
ence in effect of pcY on 7D12–EGFR interaction among
mutants. In the 7D12–EGFR domain III complex structure
(PDB ID: 4KRL), Y32, Y109, and Y113 residues in 7D12 lie
at the binding interface. Hence, in our experiments, we
expected that substituting any of these tyrosine residues with
pcY could inhibit or affect 7D12–EGFR binding. While two
of the mutants show expected behavior, i.e., significantly
reduced binding to EGFR, the third mutant does bind to
EGFR. We investigated this difference in binding behaviour
through a description of 7D12–EGFR interactions and
dynamics in the presence and absence of photocaging group,
using MD simulations.
All-atom MD simulations were performed for four
systems, starting from the 7D12–EGFR domain III crystal
structure (PDB ID: 4KRL)[23] for wt7D12, and with pcY
substitutions in mutants, 7D12pcY32, 7D12pcY109, and
7D12pcY113, respectively, in the presence of explicit water
and ions, using NAMD 2.12[28] (Page S6).
Comparing the dynamics of the systems during 300 ns
simulations each, it is seen that wt7D12 and 7D12pcY109
remain bound to EGFR, while 7D12pcY32 and 7D12pcY113
show unbinding from EGFR for prolonged periods (Fig-
ure 3A). The root mean square deviation (RMSD) of the
complex from the starting conformation (Figure 3B) shows
a larger extent of movement in 7D12pcY32 and 7D12pcY113
compared to wt7D12 and 7D12pcY109. Visual analysis as well
as measuring the number of contacts maintained by 7D12
with EGFR (Figure S11) confirms that this is due to frequent
unbinding of 7D12 in the former two systems. Furthermore,
a salt bridge formed by R30 in 7D12, and D355 in EGFR,
described in previous experimental studies to play a key role
in 7D12–EGFR binding,[23] shows frequent breakage in
7D12pcY32 and 7D12pcY113, while remaining stable for
wt7D12 and 7D12pcY109 (Figure 3B).
Looking closely at the 7D12–EGFR interface, it is seen
from the wt7D12–EGFR simulations that Y32 and Y113,
both form some non-specific interactions with EGFR, mainly
with L325, and as such any notable hydrogen bonding or
packing interactions are not seen. Upon substitution by pcY,
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in both cases, the additional o-nitrobenzyl group protrudes
into the binding interface, contacting several EGFR residues.
Although initially appearing to be accommodated at the
binding interface, as the simulation proceeds, it does not form
stable contacts that could compensate for the crowding
caused in the region, disrupting binding. On examining
Y109, which is also at the binding interface, it is seen to
remain oriented nearly parallel to the EGFR surface
throughout the wt7D12 simulations, interacting significantly
with only S418 on EGFR. The 7D12pcY109–EGFR complex
simulation demonstrates that the additional o-nitrobenzyl
group is accommodated in a large solvent-accessible cleft, not
causing steric clashes, and allowing the complex to remain
bound.
While providing an explanation for the different behavior
of the Y109 mutant, this study also demonstrates the
effectiveness of MD simulations to obtain details about
inter-residue interactions in proteins containing unnatural
amino acids. The methodology and force field parameters
developed here for pcY can also be utilized in future studies
to design a predictive protocol to determine candidate
residues for pcY substitution in other proteins.
Light-dependent delivery of fluorophores to the surface of
live EGFR-positive cancer cells.We designed experiments to
examine and provide evidence that photoactive antibodies
can mediate light-dependent delivery of small molecules to
the surface of live A431 cells. wt7D12 and 7D12pcY32 were
labeled using N-hydroxysuccinimide (NHS) ester of a fluo-
rophore, BODIPY-TMR-X (Page S6). We first assessed if the
presence of this label on 7D12 influences 7D12-EGFR
binding, using our on-cell assay. Comparison of unlabeled
and labeled 7D12 reveal that the binding is reduced by & 1.5-
fold due to the presence of the BODIPY-TMR-X label
(Figure S12), hence at least 1.5-fold higher concentration of
labeled sample would be required for further experiments.
The light-dependent localisation of photoactive antibody
on the surface of live A431 cells was evaluated using
fluorescence microscopy in a dynamic experimental setup.
The microscope was fitted with a flow chamber, with the flow
rate of media and the labeled antibody fragments fixed at
1 mLmin@1 throughout the experiment. Images were acquired
every 30 s, except during irradiation with 365 nm light. Media
was initially passed for 5 min through the chamber containing
A431 cells, followed by 500 nm solution of labeled
7D12pcY32 for 2 min, and then again media for 10 min.
Fluorescence due to the passing fluorophore, is observed only
during the passage of labeled 7D12pcY32; no signal attrib-
utable to localisation of fluorophore on the cell surface is seen
(Supporting Movie S1). Next, labeled 7D12pcY32 was again
passed through the chamber for 2 min, but this time, after
1 min, the chamber was irradiated with 365 nm light for 1 min
for decaging pcY. These irradiation conditions were seen to
exert low toxicity to A431 cells (Page S6 and Figure S13).
Subsequent to the initial fluorescence due to the movement of
labeled 7D12pcY32, localisation of fluorescence signal on the
cell surface was observed even 2 min after stopping the
injection of labeled 7D12pcY32. Comparison of fluorescence
signals observed 1.5 min after stopping the flow of labeled
7D12pcY32 without (Figure 4A), and with (Figure 4C)
irradiation, demonstrates light-dependent delivery of fluoro-
phores mediated by 7D12 to the surface of live A431 cells.
The fluorescence signal from 7D12 bound to the surface of
A431 cells eventually decays to background level, which
could possibly be due to endocytosis of 7D12, or degradation
of the fluorophore and/or photobleaching (Figure 4D).
Finally, as a control, 500 nm solution of labeled wt7D12 is
passed through the chamber for 2 min. As expected, a strong
fluorescence signal was observed over 1.5 mins after stopping
the flow of labelled wt7D12, consistent with receptor-
mediated localisation of wt7D12 (Figure 4E). The fluores-
cence signal for wt7D12 is stronger than for decaged
7D12pcY32 (Figure 4C) presumably because the latter flows
in the caged form for 1 min and decaged form for 1 min, thus
Figure 3. MD simulations of wt7D12 and its photocaged mutants
show that wt7D12 and 7D12pcY109 form more stable complexes with
EGFR domain III as compared to 7D12pcY32 and 7D12pcY113.
A) Simulation snapshots taken at intervals of 30 ns during 300 ns
simulations for each system, (EGFR: grey for all, wt7D12: black,
7D12pcY32: red, 7D12pcY109: green, 7D12pcY113: blue) highlight the
extent of motion of 7D12. B) Left: RMSDs from starting structure for
protein Ca atoms during simulations show large deviations for
7D12pcY32 and 7D12pcY113. Right: The R30–D355 salt-bridge (resi-
dues shown in (A) wt7D12 snapshot, in yellow), monitored as the
distance between the R30 guanidine C and the D355 carboxyl C, breaks
frequently in the 7D12pcY32 and 7D12pcY113 systems. These observa-
tions suggest that the presence of pcY at positions 32 and 113
destabilizes the 7D12–EGFR domain III complex.
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reducing the effective concentration of actively binding 7D12,
when compared to wt7D12 that flows for 2 min. Overall, these
results are consistent with light-dependent delivery of fluo-
rophores on the surface of EGFR-positive cancer cells.
This fluorescence microscopy study demonstrates that
photoactive antibodies can deliver small molecules to the
surface of specific cancer cells in a light-dependent manner.
Extending these antibodies to deliver cytotoxic drugs will
provide a highly targeted, light-mediated and receptor-
specific approach for cancer therapy.
The photoactive antibody fragments developed in this
report have a molecular weight difference of less than 1%
from wild type, and hence expected to have similar pharma-
cokinetic properties. Introducing such modifications in cur-
rently used therapeutic antibodies could allow 365 nm UV
light-assisted targeting of cancer cells close to the skin surface.
It has been shown that UV radiations can penetrate through
murine skin to activate intradermally injected light-sensitive
therapeutics.[29] UV light is also being used clinically in
combination with the drug, psoralen, for treatment of skin
cancer.[30] LEDs emitting UV light are under investigation for
treatment of Vitamin D deficiency,[31] and, there have been
investigations on activation of antibody-based drugs using
UV radiations, for treatment of ovarian cancer in mice
models.[10b] The extension of the present work towards
utilizing near-infrared (IR) radiation instead of UV, is
expected to widen its applicability as IR radiation penetrates
deeper into tissue. The use of near-IR light assisted by
upconverting nanoparticles[32] or two-photons[33] may also
allow activation of UV-sensitive photocaged antibodies in
deeper tissues. Photoactive antibodies may also be useful for
treatment of tumors in body parts where surgical implanta-
tion of biocompatible light emitting diodes (LEDs)[34] is
possible and photoactivation can be achieved using these
LEDs.
Conclusion
We report highly efficient genetic site-specific incorpo-
ration of unnatural amino acids into the antibody fragment,
7D12, expressed in E. coli. Replacement of specific tyrosine
residues with unnatural photocaged tyrosine in the antigen
binding site of 7D12, resulted in development of photoactive
antibodies. Light-mediated binding of photoactive antibodies
to their target, EGFR, was demonstrated using a robust and
simple assay performed on the surface of cancer cells.
Computational methods were used to study the dynamics of
7D12–EGFR interaction and explain the effect of the photo-
caging group when placed at different sites in the 7D12–
EGFR binding interface. Finally, we show in a dynamic
fluorescence microscopy experiment that photoactive anti-
bodies can deliver small molecules to the surface of live
cancer cells in a light-dependent manner. This demonstration
of the use of genetically encoded photocaged amino acids to
control antibody binding, opens a new dimension in the field
of controlled antibody-antigen interactions, with the potential
for widespread applications to biotherapeutics and nano-
technology.
Figure 4. Light-mediated delivery of fluorophores by photoactive antibodies on live A431 cells. A) Labeled 7D12pcY32 is injected at 5 min. Near-
background fluorescence is observed 1.5 min after passing labeled 7D12pcY32 over live A431 cells demonstrating that due to the presence of
caged group, 7D12pcY32 does not bind to the cell surface. B) Background fluorescence before re-injecting labeled 7D12pcY32. C) Labeled
7D12pcY32 was injected at 17 min and the irradiated with 365 nm light at 18 min (1 min after injecting 7D12pcY32) for 1 min. Significant
fluorescence was observed 1.5 min after stopping the injection of labeled 7D12pcY32, demonstrating light-dependent localisation of 7D12 on the
surface of A431 cells. D) Fluorescence from 7D12 reduces to background level. E) Labeled wt7D12 was injected at 29 min. Significant fluorescence
observed 1.5 min after stopping the injection of labeled wt7D12 due to localisation of labeled wt7D12 on the surface of A431 cells.
F) Fluorescence from wt7D12 slowly reduces to near background level. See Movie S1 in the Supporting Information.
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